May 16, 2018 / 10:26 PM / 7 days ago

BRIEF-CORRECTED-(OFFICIAL)-Veloxis Pharmaceuticals maintains 2018 Outlook Of Revenues (May 14)

May 16 (Reuters) - Veloxis Pharmaceuticals A/S:

* VELOXIS PHARMACEUTICALS - MAINTAINS ITS 2018 OUTLOOK OF OPERATING LOSS BEFORE ACCOUNTING FOR STOCK COMPENSATION IN RANGE OF USD 6 MILLION–12 MILLION

* REG-VELOXIS PHARMACEUTICALS ANNOUNCES FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2018

* QTRLY PRODUCT REVENUE FOR Q1 2018 WAS TUSD 7,265 AN INCREASE OF 142% COMPARED TO SAME PERIOD LAST YEAR

* VELOXIS MAINTAINS ITS 2018 OUTLOOK OF REVENUES TO BE IN RANGE OF USD 32 MILLION- USD 40 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below